Chemomab Therapeutics (CMMB) Current Assets (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Current Assets came in at $13.4 million in Q4 2025, down 16.3% YoY from $16.0 million in Q4 2024, and up 12.57% on a QoQ basis from $11.9 million in Q3 2025.
Chemomab Therapeutics (CMMB) Current Assets (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of Current Assets data on file, last reported at $13.4 million in Q4 2025.
- Quarterly Current Assets fell 16.3% year-over-year to $13.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.4 million (down 16.3% YoY) and the FY2025 annual result came in at $13.4 million, down 16.3% from the prior year.
- Current Assets climbed to $13.4 million in Q4 2025, from $11.9 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $68.8 million in Q2 2021 to a low of $10.6 million in Q2 2025.
- A 5-year average of $34.0 million and a median of $25.0 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2021 — Current Assets jumped 791.2% — and 2023, when it sank 54.1%.
- Tracing CMMB's Current Assets over 5 years: stood at $62.7 million in 2021, then plunged by 33.42% to $41.7 million in 2022, then plunged by 49.93% to $20.9 million in 2023, then dropped by 23.24% to $16.0 million in 2024, then retreated by 16.3% to $13.4 million in 2025.
- The last three Current Assets figures came in at $13.4 million (Q4 2025), $11.9 million (Q3 2025), and $10.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | 13.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.43 Mn |
| Sep 30, 2025 | 11.93 Mn |
| Jun 30, 2025 | 10.61 Mn |
| Mar 31, 2025 | 11.98 Mn |
| Dec 31, 2024 | 16.04 Mn |
| Sep 30, 2024 | 19.89 Mn |
| Jun 30, 2024 | 13.46 Mn |
| Mar 31, 2024 | 16.84 Mn |
| Dec 31, 2023 | 20.90 Mn |
| Sep 30, 2023 | 22.37 Mn |
| Jun 30, 2023 | 27.71 Mn |
| Mar 31, 2023 | 33.78 Mn |
| Dec 31, 2022 | 41.74 Mn |
| Sep 30, 2022 | 48.73 Mn |
| Jun 30, 2022 | 54.83 Mn |
| Mar 31, 2022 | 59.34 Mn |
| Dec 31, 2021 | 62.69 Mn |
| Sep 30, 2021 | 65.84 Mn |
| Jun 30, 2021 | 68.84 Mn |
| Mar 31, 2021 | 59.52 Mn |